ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

NCI Staff Recommends Moving Cooperative Groups Into DCT, Increase Funding, Switch Emphasis

July 4, 1975

Firm Begins Phase II Trial Of LDP-341 For Myeloma.

March 30, 2001

In Brief: Two Major Appointments Made At Fox Chase; HHS Names Task Force to Look At DRG Research Impact

April 20, 1984

DCE Board Oks Concept For Three Contracts In Radiation Epidemiology

June 29, 1984

DCT Board Restores Funding to Rosenberg’s Lymphocyte Projects

June 17, 1994

Conversation with The Cancer Letter: Scott Soefje: “These are Life-Saving Drugs. I’m Not Going To Stop Treating Patients, Right?”

October 3, 2014